ABAT
Basic information
Region (hg38): 16:8674596-8784575
Links
Phenotypes
GenCC
Source:
- GABA aminotransaminase deficiency (Limited), mode of inheritance: AR
- GABA aminotransaminase deficiency (Moderate), mode of inheritance: AR
- GABA aminotransaminase deficiency (Strong), mode of inheritance: AR
- GABA aminotransaminase deficiency (Supportive), mode of inheritance: AR
- genetic developmental and epileptic encephalopathy (Moderate), mode of inheritance: AR
- GABA aminotransaminase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
GABA-transaminase deficiency | AR | Biochemical | The condition includes neonatal or early-onset neurologic sequelae, and medical management (with continuous flumazenil) has been described as beneficial in a patient with a milder phenotype | Biochemical; Neurologic | 6148708; 4020531; 10407778; 27596361; 28411234 |
ClinVar
This is a list of variants' phenotypes submitted to
- Gamma-aminobutyric_acid_transaminase_deficiency (589 variants)
- Inborn_genetic_diseases (57 variants)
- not_provided (55 variants)
- not_specified (11 variants)
- ABAT-related_disorder (9 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ABAT gene is commonly pathogenic or not. These statistics are base on transcript: NM_000020686.6. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 158 | 167 | ||||
missense | 224 | 242 | ||||
nonsense | 12 | |||||
start loss | 1 | 1 | ||||
frameshift | 9 | |||||
splice donor/acceptor (+/-2bp) | 13 | |||||
Total | 14 | 27 | 234 | 164 | 5 |
Highest pathogenic variant AF is 0.00000743752
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ABAT | protein_coding | protein_coding | ENST00000396600 | 15 | 110011 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00632 | 0.994 | 125730 | 0 | 18 | 125748 | 0.0000716 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.573 | 266 | 294 | 0.906 | 0.0000196 | 3317 |
Missense in Polyphen | 57 | 99.401 | 0.57343 | 1030 | ||
Synonymous | -0.642 | 127 | 118 | 1.08 | 0.00000863 | 931 |
Loss of Function | 3.29 | 9 | 27.7 | 0.325 | 0.00000140 | 317 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000904 | 0.0000904 |
Ashkenazi Jewish | 0.000298 | 0.000298 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000933 | 0.0000924 |
European (Non-Finnish) | 0.0000890 | 0.0000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the conversion of gamma-aminobutyrate and L- beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Butanoate metabolism - Homo sapiens (human);beta-Alanine metabolism - Homo sapiens (human);Propanoate metabolism - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);Valproic Acid Pathway, Pharmacodynamics;Pathway_PA165964473;Carnosinuria, carnosinemia;Ureidopropionase deficiency;GABA-Transaminase Deficiency;3-Methylglutaconic Aciduria Type I;Valine, Leucine and Isoleucine Degradation;2-Hydroxyglutric Aciduria (D And L Form);2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;Malonyl-coa decarboxylase deficiency;Beta-Alanine Metabolism;Malonic Aciduria;Hypoacetylaspartia;Isovaleric Aciduria;3-Methylcrotonyl Coa Carboxylase Deficiency Type I;Propionic Acidemia;Maple Syrup Urine Disease;Propanoate Metabolism;3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency;Isobutyryl-coa dehydrogenase deficiency;3-hydroxyisobutyric aciduria;3-hydroxyisobutyric acid dehydrogenase deficiency;Isovaleric acidemia;Aspartate Metabolism;Homocarnosinosis;Methylmalonate Semialdehyde Dehydrogenase Deficiency;Hyperinsulinism-Hyperammonemia Syndrome;Succinic semialdehyde dehydrogenase deficiency;Methylmalonic Aciduria;Methylmalonic Aciduria Due to Cobalamin-Related Disorders;3-Methylglutaconic Aciduria Type IV;3-Methylglutaconic Aciduria Type III;4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;Glutamate Metabolism;Beta-Ketothiolase Deficiency;Canavan Disease;Alanine and aspartate metabolism;Valproic acid pathway;Alanine Aspartate Asparagine metabolism;Glutamate Glutamine metabolism;Neuronal System;valine degradation;Histidine metabolism;Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine;Valine, leucine and isoleucine degradation;Arginine Proline metabolism;GABA shunt;Pyrimidine nucleotides nucleosides metabolism;Degradation of GABA;GABA synthesis, release, reuptake and degradation;Neurotransmitter release cycle;Transmission across Chemical Synapses;4-aminobutyrate degradation;β-alanine degradation
(Consensus)
Intolerance Scores
- loftool
- 0.106
- rvis_EVS
- -0.33
- rvis_percentile_EVS
- 30.74
Haploinsufficiency Scores
- pHI
- 0.410
- hipred
- Y
- hipred_score
- 0.554
- ghis
- 0.562
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.940
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Abat
- Phenotype
Gene ontology
- Biological process
- response to hypoxia;aging;copulation;locomotory behavior;gamma-aminobutyric acid biosynthetic process;gamma-aminobutyric acid catabolic process;response to iron ion;negative regulation of gamma-aminobutyric acid secretion;cerebellum development;positive regulation of heat generation;positive regulation of insulin secretion;negative regulation of dopamine secretion;response to nicotine;exploration behavior;neurotransmitter catabolic process;response to ethanol;negative regulation of blood pressure;positive regulation of dopamine metabolic process;behavioral response to cocaine;positive regulation of uterine smooth muscle contraction;negative regulation of platelet aggregation;positive regulation of inhibitory postsynaptic potential;positive regulation of prolactin secretion;positive regulation of aspartate secretion
- Cellular component
- mitochondrion;mitochondrial matrix;4-aminobutyrate transaminase complex;neuron projection
- Molecular function
- 4-aminobutyrate transaminase activity;pyridoxal phosphate binding;succinate-semialdehyde dehydrogenase binding;4-aminobutyrate:2-oxoglutarate transaminase activity;protein homodimerization activity;metal ion binding;(S)-3-amino-2-methylpropionate transaminase activity;iron-sulfur cluster binding